+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cyclosporine drugs Market 2020-2026

  • PDF Icon


  • June 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129756
UP TO OFF until Dec 31st 2022
Global Cyclosporine drugs Market Size, Share & Trends Analysis Report, by Indication (Rheumatoid Arthritis, Psoriasis, Transplant Rejection Prophylaxis, Dry Eye, Autoimmune Myasthenia Gravis and Other), by Route of Administration (Oral and Parenteral) and Forecast Period, 2020-2026
The global cyclosporine drug market is estimated to grow at a moderate CAGR during the forecast period. The rising prevalence of rheumatoid arthritis and transplant rejection prophylaxis is expected to create demand for cyclosporine drug across the globe. The Centers for Disease Control and Prevention (CDC), in March 2017, estimated that 54.4 million US adults suffer from arthritis - equating to about 25% of the population. Arthritis is the leading cause of disability and causes pain, aching, stiffness, and swelling of the joints. Cyclosporine drug decreases the pain and swelling of arthritis, and may also prevent joint damage and reduce the risk of long term disability.

The global cyclosporine drugs market is segmented based on indication and route of administration. Based on indication, the market is classified into rheumatoid arthritis, psoriasis, transplant rejection prophylaxis, dry eye, and autoimmune myasthenia gravis and others. Based on the route of administration, the market is classified into oral and parenteral. Geographically, the global Cyclosporine drugs market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The market in the Asia-Pacific region is estimated to grow significantly due to various factors such as an increase in awareness among the population, a rise in disposable income and improved healthcare sector.

The major companies providing cyclosporine drugs include Allergan PLC, Sun Pharmaceuticals Industries, Ltd. Novartis AG, Teva Pharmaceuticals Industries, Ltd., Apotex Inc., Otsuka Pharmaceutical Co. Ltd., Regenerx Biopharmaceuticals, Inc., and Takeda Pharmaceutical Co. Ltd. These players are adopting various strategies in order to sustain in the global market. For instance, in May 2018, Teva Canada launched Teva-Cyclosporine ophthalmic emulsion, the first generic version of Restasis in Canada for the treatment of dry eye disease.

Research Methodology

The market study of the global cyclosporine drugs market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Authentic public databases
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:
  • Global Cyclosporine Drugs Market Research and Analysis by Indication
  • Global Cyclosporine Drugs Market Research and Analysis by Route of Administration

The Report covers:
  • Comprehensive research methodologies of the global cyclosporine drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global cyclosporine drugs market.
  • Insights about market determinants which are stimulating the global cyclosporine drugs market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Allergan PLC Overview Financial Analysis SWOT Analysis Recent Developments
3.3.2. Sun Pharmaceuticals Industries, Ltd. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.3. Novartis AG Overview Financial Analysis SWOT Analysis Recent Developments
3.3.4. Teva Pharmaceuticals Industries, Ltd. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.5. Apotex Inc. Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Cyclosporine Drugs Market by Indication
5.1.1. Transplant Rejection Prophylaxis
5.1.2. Rheumatoid Arthritis
5.1.3. Psoriasis
5.1.4. Dry Eye
5.1.5. Autoimmune Myasthenia Gravis
5.1.6. Others
5.2. Global Cyclosporine Drugs Market by Route of Administration
5.2.1. Oral
5.2.2. Parenteral
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AbbVie Inc.
7.2. Allergan PLC
7.3. Apotex, Inc.
7.4. Mayne Pharma Group Ltd.
7.5. Mckesson Medical Surgical Inc.
7.6. Novartis AG
7.7. Otsuka Pharmaceutical Co. Ltd.
7.8. Regenerx Biopharmaceuticals, Inc.
7.9. Santen Pharmaceuticals Co. Ltd.
7.10. Sun Pharmaceuticals Industries, Ltd.
7.11. Takeda Pharmaceutical Co. Ltd.
7.12. Teva Pharmaceuticals Industries, Ltd.
7.13. United Biotech Pvt. Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Allergan PLC
  • Apotex, Inc.
  • Mayne Pharma Group Ltd.
  • Mckesson Medical Surgical Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co. Ltd.
  • Regenerx Biopharmaceuticals, Inc.
  • Santen Pharmaceuticals Co. Ltd.
  • Sun Pharmaceuticals Industries, Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceuticals Industries, Ltd.
  • United Biotech Pvt. Ltd.